- Home
- ACIU vs ZURA Comparison
ACIU vs ZURA Comparison
Compare ACIU & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | ZURA |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 252.9M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIU | ZURA |
|---|---|---|
| Price | $3.33 | $5.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.00 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 1.4M | 549.2K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,482,957.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $644.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.97 |
| 52 Week High | $4.00 | $5.62 |
Technical Indicators
Market Signals| Indicator | ACIU | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 79.70 |
| Support Level | $3.02 | $5.07 |
| Resistance Level | $3.30 | $5.62 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 49.46 | 88.77 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.